The Bajaj Healthcare Ltd share has surged 11 per cent to Rs 1,009.80 on the BSE in intra-day trade on Thursday after the company received a licence from Defence Research and Development Organisation (DRDO) to manufacture and market ‘2-Deoxy-D-Glucose’ (2-DG) as approved medication for the treatment of COVID-19 patients.
‘2-DG helps in the faster recovery of hospitalized patients and reduces supplemental oxygen dependence. The drug works by selectively accumulating in the virus-infected cells and prevents virus growth by stopping viral synthesis and energy production. It can be administered only upon prescription and under the supervision of a qualified physician to hospitalized moderate to severe COVID-19 patients as an adjunct therapy to the existing standard of care,’ Bajaj Healthcare said in a release.
- India sees minimal impact from US trade policies, but risks persist: UBI Report
- Perplexity in Early Funding Talks at $18 Billion Valuation
- Toyota to Launch First India R&D Hub, Plans 1,000 Engineers & EV Expansion by 2027
- Trump Announces Upcoming US-Ukraine Minerals Deal
- Mazagon Dock, Goa Tie Up for AI-Based Disaster Management; Shares Fall 1%
Bajaj Healthcare is a leading manufacturer of active pharmaceutical ingredients (APIs), intermediates, and formulations. It was for the ninth straight day that the stock of the pharmaceutical company was trading higher, having gained 43 per cent during the period. In the past three months, it has soared 120 per cent as compared to a 7 per cent rise in the S&P BSE Sensex.
Stock Covered in the news
